A Phase 3 interventional study of Lurasidone 20, 40, 60, 80 mg, flexibly dosed in Schizophrenia, Autism and Bipolar Depression, sponsored by Sumitomo Pharma America, Inc.. Completed at 88 sites in 15 countries. Open to participants aged 6 Years to 17 Years. Per ClinicalTrials.gov, last updated 2019-12-19.
Sponsored by Sumitomo Pharma America, Inc. (part of Sumitomo Pharma Co., Ltd.) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 39 studies testing lurasidone in Schizophrenia — none open to participants now, none under way, none of them phase 3. lurasidone · Schizophrenia.
Among the 39 studies testing lurasidone in Schizophrenia, this one has the largest enrollment, is one of 5 that started in 2013, is one of 18 in phase 3, and was the 27th registered.
3,571 studies on the registry are indexed under Schizophrenia; 493 are open to participants now.
Browse Schizophrenia studies →None of the 39 studies testing lurasidone in Schizophrenia is open now. The open studies under Schizophrenia, anywhere →
lurasidone: first FDA approval 2010 (LATUDA), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →
Of the 332 Schizophrenia studies recruiting now, 63 (19%) set no upper age limit and 258 (78%) stop at 75 or younger; 42 take children under 18; 83 take healthy volunteers.
This study: 6 Years to 17 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
39 studies; the count open now beside each. This study's row is marked.
First in 2002; this study’s year is marked. 5 started in 2013.
This study's enrollment of 702 is above the median of 71 across 2,947 interventional studies indexed under Schizophrenia.
Median enrollment 149 across the 39 interventional studies. Of the 38 that completed or were terminated, 27 (71%) have results posted.
This tab as a report to print or save as PDF → With an account.
33 of 39 have an industry lead sponsor. The 10 most frequent:
This study is registered under Sumitomo Pharma America, Inc., one of the names counted as Sumitomo Pharma Co., Ltd.. Under that name alone:
Sumitomo Pharma America, Inc. is the lead sponsor of 181 studies on the registry; 5 are open to participants now.
Of its 33 completed or terminated interventional studies of FDA-regulated products, 21 (64%) have results posted.
40 studies in Schizophrenia by Sumitomo Pharma Co., Ltd.: none open now, none under way, none of them phase 3. Of 40 finished, 28 (70%) have results posted.
Among the 40 studies in Schizophrenia by Sumitomo Pharma Co., Ltd., this one has the largest enrollment of the 39 interventional ones that give a count, is one of 4 that started in 2013, is one of 21 in phase 3, and was the 27th registered.
Sumitomo Pharma Co., Ltd.’s Schizophrenia studies by the year they started, since 2002.
None of the studies under way reaches primary completion within a year.
Among the 39 studies testing lurasidone in Schizophrenia, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Sumitomo Pharma Co., Ltd.’s 40 in Schizophrenia:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This is an open-label, 104-week, multicenter, extension study designed to evaluate the long-term safety, tolerability and effectiveness of flexibly dosed lurasidone (20, 40, 60 or 80 mg/day) in pediatric subjects who have completed the 6-week treatment period in the preceding studies, D1050301, D1050325, and D1050326
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Females who participate in this study:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Lurasidone 20, 40, 60, 80 mg, flexibly dosed, once daily
Drug: Lurasidone 20, 40, 60, 80 mg, flexibly dosed
Lurasidone 20, 40, 60, 80 mg once daily, flexibly dosed
Also known as: Latuda
Number of Subjects With Adverse Events (AEs), Discontinuations Due to AEs and Serious AEs (SAEs)
The Safety population consists of all subjects who received at least one dose of study drug in this study.
Time frame: During 104 Weeks (2-years) treatment period
Change From Baseline in the Positive and Negative Syndrome Scale (PANSS) Total Score
Change from Baseline in the Positive and Negative Syndrome Scale (PANSS) Total Score for subjects continued from study D1050301. PANSS is comprised of 30 items and 3 subscales (Positive, Negative, General Psychopathology). An anchored Likert scale from 1 - 7, where values of 2 and above indicate the presence of progressively more severe symptoms, is used to score each item. Individual items are then summed to determine scores for the 3 subscales, as well as a total score. PANSS Positive subscale score range: 7-49. PANSS Negative subscale score range: 7-49. PANSS General Psychopathology subscale score range: 16-112. PANSS total score range: 30-210 Higher values of PANSS total score represents greater severity of illness.
Time frame: Open-Label Baseline, Week 28, Week 52, and Week 104
Change From Baseline in PANSS Positive Subscale Score
Change from Baseline in PANSS Positive Subscale Score for subjects continued from study D1050301 The Positive scale contains seven questions to assess delusions, conceptual disorganization, hallucinations behavior, excitement, grandiosity, suspiciousness /persecution, and hostility; Positive subscale (range 7-49) is calculated as sum of Items P1 to P7 in the positive subscale Higher values of PANSS sub-scale scores represent greater severity
Time frame: Open-Label Baseline, Week 28, Week 52, and Week 104
Change From Baseline in PANSS Negative Subscale Score
Change from Baseline in PANSS Negative Subscale Score for subjects continued from study D1050301 The Negative scale contains seven questions to assess blunted effect, emotional withdrawal, poor rapport, passive/apathetic social withdrawal, lack of motivation, and similar symptoms; Negative subscale (range 7-49) is calculated as sum of Items N1 to N7 in the negative subscale Higher values of PANSS sub-scale scores represent greater severity of illness.
Time frame: Open-Label Baseline, Week 28, Week 52, and Week 104
Change From Baseline in PANSS General Psychopathology Subscale Score
Change from Baseline in PANSS General Psychopathology Subscale Score for subjects continued from study D1050301 The General Psychopathology subscale addresses other symptoms such as anxiety, somatic concern, and disorientation; General psychopathology subscale (range 16-112) is calculated as sum of Items G1 to G16 in the general psychopathology subscale Higher values of PANSS sub-scale scores represent greater severity of illness.
Time frame: Open-Label Baseline, Week 28, Week 52, and Week 104
Change From Baseline in PANSS Excitability Subscale Score
Change from Baseline in PANSS Excitability Subscale Score for subjects continued from study D1050301 Subscale of Excitability consists of the following four items from the PANSS: excitement, hostility, uncooperativeness, and poor impulse control. The sum of the four items ranges from 4 to 28 Higher values of PANSS sub-scale scores represent greater severity of illness.
Time frame: Open-Label Baseline, Week 28, Week 52, and Week 104
Change From Baseline in the Clinical Global Impression -Severity Score
Change from Baseline in the Clinical Global Impression -Severity Score for subjects continued from study D1050301 The CGI-S is a single value, clinician-rated assessment of illness severity, and 7-point scale with range from 1='Normal, not at all ill' to 7='Among the most extremely ill patients'. A higher score is associated with greater illness severity
Time frame: Open-Label Baseline, Week 28, Week 52, and Week 104
Change From Baseline in Clinician-Rated Children's Global Assessment Score (CGAS) Score
Change from Baseline in Clinician-Rated Children's Global Assessment Score (CGAS) Score for subjects continued from study D1050301 The Children's Global Assessment Scale (CGAS) is a numeric scale (1 through 100) used by mental health clinicians to rate the general functioning of children under the age of 18, where 1 represents the most impaired functioning and 100, superior functioning. Each decile (e.g., 1-10, 11-20) has a descriptive header (e.g., "Moderate impairment in functioning in most domains") and examples of behaviors and types of environmental accommodations that might be seen at that level of functioning. Scores above 70 on the CGAS indicate functioning within the range of typically developing children of the same age as the child being rated while scores below 60 indicate a definite clinical case
Time frame: Open-Label Baseline, Week 28, Week 52, and Week 104
Change From Baseline in Pediatric Quality of Life Enjoyment and Satisfaction Questionnaire (PQ-LES-Q) Percentage Maximum Possible Score
Change from Baseline in Pediatric Quality of Life Enjoyment and Satisfaction Questionnaire (PQ-LES-Q) Percentage Maximum Possible Score for subjects continued from study D1050301 The Pediatric Q-LES-Q is a 15-item self-report measure of the degree of enjoyment and satisfaction in various areas of daily living, based on the content of the Short From of the Q-LES-Q. Each item is rated on a 5-point scale, ranging from 1 (very poor) to 5 (very good). The first 14 items are the same as the General Activities section of the regular Q-LES-Q form and are used to compute the raw score. The PQ-LES-Q-SF percentage maximum possible score is calculated as follows: % Max = 100 × (Raw Score - Minimum Score) / (Maximum Score - Minimum Score), where the Minimum Score equals 14 and the Maximum Score equals 70, and the % maximum possible score can range from 0% to 100%. Higher scores indicate better quality of life.
Time frame: Open-Label Baseline, Week 28, Week 52, and Week 104
Change From Baseline in Aberrant Behavior Checklist (ABC) Irritability Subscale Score
Change from Baseline in ABC Irritability Subscale Score for subjects continued from study D1050325 The Aberrant Behavior Checklist (ABC) contains 58 items resolve into five subscales: (1) irritability and agitation (15 items), (2) lethargy and social withdrawal (16 items), (3) stereotypic behavior (7 items), (4) hyperactivity and noncompliance (16 items), and (5) inappropriate speech (4 items). Each item is rated for severity on a 4-point Likert scale ranging from 0 (not at all a problem) to 3 (the problem is severe in degree). Irritability Subscale Score is calculated as summing of items 2, 4, 8, 10, 14, 19, 25, 29, 34, 36, 41, 47, 50, 52, and 57; as a result, ABC irritability subscale score ranges from 0 to 45. In general, higher values of ABC subscale scores represent greater severity of illness. If one or more items are missing, no imputation was performed and the scores of the subscales that include these items was left missing
Time frame: Open-Label Baseline, Week 28, Week 52, and Week 104
Change From Baseline in Aberrant Behavior Checklist (ABC) Lethargy and Social Withdrawal Subscale Score
Change from Baseline in ABC Lethargy and Social Withdrawal Subscale Score for subjects continued from study D1050325 The ABC contains 58 items resolve into five subscales: (1) irritability and agitation (15 items), (2) lethargy and social withdrawal (16 items), (3) stereotypic behavior (7 items), (4) hyperactivity and noncompliance (16 items), and (5) inappropriate speech (4 items). Each item is rated for severity on a 4-point Likert scale ranging from 0 (not at all a problem) to 3 (the problem is severe in degree). Lethargy and Social Withdrawal Subscale Score is calculated as summing of items 3, 5, 12, 16, 20, 23, 26, 30, 32, 37, 40, 42, 43, 53, 55, and 58. ABC Lethargy and Social Withdrawal Subscale Score ranges from 0 to 48. In general, higher values of ABC subscale scores represent greater severity of illness. If one or more items are missing, no imputation was performed and the scores of the subscales that include these items was left missing
Time frame: Open-Label Baseline, Week 28, Week 52, and Week 104
Change From Baseline in Aberrant Behavior Checklist (ABC) Stereotypic Behavior Subscale Score
Change from Baseline in ABC Stereotypic Behavior Subscale Score for subjects continued from study D1050325. The ABC contains 58 items resolve into five subscales: (1) irritability and agitation (15 items), (2) lethargy and social withdrawal (16 items), (3) stereotypic behavior (7 items), (4) hyperactivity and noncompliance (16 items), and (5) inappropriate speech (4 items). Stereotypic behavior Subscale Score is calculated as summing of 6, 11, 17, 27, 35, 45, and 49 items . ABC Stereotypic behavior Subscale Score ranges from 0 to 21. Each item is rated for severity on a 4-point Likert scale ranging from 0 (not at all a problem) to 3 (the problem is severe in degree). To score the ABC, the individual items for each subscale are simply summed to their respective totals. It is inappropriate to compute a "total aberrant score", based on a summation of all 58 items, as the subscales are largely independent. In general, higher values of ABC subscale scores represent greater severity
Time frame: Open-Label Baseline, Week 28, Week 52, and Week 104
Change From Baseline in Aberrant Behavior Checklist (ABC) Hyperactivity and Noncompliance Subscale Score
Change from Baseline in ABC Hyperactivity and Noncompliance Subscale Score for subjects continued from study D1050325 The ABC contains 58 items resolve into five subscales: (1) irritability and agitation (15 items), (2) lethargy and social withdrawal (16 items), (3) stereotypic behavior (7 items), (4) hyperactivity and noncompliance (16 items), and (5) inappropriate speech (4 items). Each item is rated for severity on a 4-point Likert scale ranging from 0 (not at all a problem) to 3 (the problem is severe in degree). Hyperactivity and noncompliance Subscale Score is calculated as summing of 1, 7, 13, 15, 18, 21, 24, 28, 31, 38, 39, 44, 48, 51, 54, and 56 items. ABC hyperactivity and noncompliance Subscale Score ranges from 0 to 48. In general, higher values of ABC subscale scores represent greater severity of illness. If one or more items are missing, no imputation was performed and the scores of the subscales that include these items was left missing
Time frame: Open-Label Baseline, Week 28, Week 52, and Week 104
Change From Baseline in Aberrant Behavior Checklist (ABC) Inappropriate Speech Subscale Score
Change from Baseline in ABC Inappropriate Speech Subscale Score for subjects continued from study D1050325 The ABC contains 58 items resolve into five subscales: (1) irritability and agitation (15 items), (2) lethargy and social withdrawal (16 items), (3) stereotypic behavior (7 items), (4) hyperactivity and noncompliance (16 items), and (5) inappropriate speech (4 items). Each item is rated for severity on a 4-point Likert scale ranging from 0 (not at all a problem) to 3 (the problem is severe in degree). Inappropriate speech Subscale Score is calculated as summing of 9, 22, 33, and 46 items. ABC inappropriate speech Subscale Score ranges from 0 to 12. In general, higher values of ABC subscale scores represent greater severity of illness. If one or more items are missing, no imputation was performed and the scores of the subscales that include these items was left missing
Time frame: Open-Label Baseline, Week 28, Week 52, and Week 104
Change From Baseline in Clinical Global Impression (CGI) - Severity Score
Change from Baseline in Clinical Global Impression (CGI) - Severity Score for subjects continued from study D1050325 The CGI-S is a single value, clinician-rated assessment of illness severity, and 7-point scale with range from 1='Normal, not at all ill' to 7='Among the most extremely ill patients'. A higher score is associated with greater illness severity
Time frame: Open-Label Baseline, Week 28, Week 52, and Week 104
Change From Baseline in Children's Yale-Brown Obsessive Compulsive Score (CY-BOCS)
Change from Baseline in CY-BOCS for subjects continued from study D1050325 CY-BOCS used in the study is a modification of the Yale-Brown Obsessive Compulsive Scale and contains total 7 items for compulsion. "Obsessions" section was removed as it is difficult to obtain valid information given typical language/cognitive delays in the population. Each item of the compulsive scale ranges from 0 to 4. At this time, item 1b ("compulsion-free interval") and item 6 ("peculiarity of the behavior") are not being used in the scoring. Item 7 is a rating for reliability, ranging from 0 (excellent) to 3 (poor). It reflects the interview's judgment regarding the confidence in the data collected hence it is not counted in the CY-BOCS total score. The CY-BOCS compulsion total score is the sums of item 1-5. As a result, the CY-BOCS compulsion total score may range from 0 to 20. In general, higher values of CY-BOCS scores represent greater severity of illness
Time frame: Open-Label Baseline, Week 28, Week 52, and Week 104
Change From Baseline in Caregiver Strain Questionnaire (CGSQ) Global Strain Score
Change from Baseline in Caregiver Strain Questionnaire (CGSQ) Global Strain Score for subjects continued from study D1050325 The CGSQ is comprised of total 21 items. Each item is rated on a 5-point Likert-type scale (1 (not at all a problem) to 5 (very much a problem)) and is grouped into three subscales: objective strain, subjective externalized strain, and subjective internalized strain. The 3 subscale scores are calculated as the averages of the corresponding individual items, which range in severity from 1 to 5. Higher scores on each of these subscale scales indicate greater strain. A global strain score is calculated by summing the three subscales (i.e., objective strain, subjective externalized strain, and subjective internalized strain) to provide an indication of the total impact of the special demands on the family. Global strain scores range from 3 to 15. As with the individual subscales, higher scores indicate greater strain
Time frame: Open-Label Baseline, Week 28, Week 52, and Week 104
Change From Baseline in Children's Depression Rating Scale, Revised (CDRS-R) Total Score
Change from Baseline in CDRS-R Total Score for subjects continued from study D1050326 CDRS-R is a semi-structured, clinician-rated instrument designed for use with children and adolescents between the ages of 6 17 years. It contains 17 ordinally-scaled items that evaluate the presence and severity of symptoms commonly associated with depression in childhood. The CDRS-R is administered separately to the patient and to the caregiver; among 17 items, 14 items are based on separate interviews with child and parent, 3 items are based solely on the rater's observation of child (ie, no questions).The 14 items are rated on a 1 (no psychopathology) to 7 (most psychopathology) scale, where a rating of 3 represents mild psychopathology. The 3 items (sleep disturbance, appetite disturbance, listless speech) are rated on a 1 (no pathology) to 5 (most pathology) scale. The CDRS-R total score ranges from 17-113. In general, higher values of CDRS-R total score represent greater severity of illness
Time frame: Open-Label Baseline, Week 28, Week 52, and Week 104
Change From Baseline in Clinical Global Impression Bipolar Version (CGI-BP-S) Depression Score
Change from Baseline in Clinical Global Impression Bipolar Version (CGI-BP-S) Depression Score for subjects continued from study D1050326 The CGI-BP-S is a three-question clinician-rated assessment of the subject's current illness state (depression, mania, and overall) using a 7-point scale (1(normal, not ill) to 7 (very severely ill)) for each question, where a higher score is associated with greater illness severity.
Time frame: Open-Label Baseline, Week 28, Week 52, and Week 104
Change From Baseline in Clinician-rated Children's Global Assessment Scale (CGAS) Score
Change from Baseline in Clinician-rated Children's Global Assessment Scale (CGAS) Score for subjects continued from study D1050326 The Children's Global Assessment Scale (CGAS) is a numeric scale (1 through 100) used by mental health clinicians to rate the general functioning of children under the age of 18, where 1 represents the most impaired functioning and 100, superior functioning. Each decile (e.g., 1-10, 11-20) has a descriptive header (e.g., "Moderate impairment in functioning in most domains") and examples of behaviors and types of environmental accommodations that might be seen at that level of functioning. Scores above 70 on the CGAS indicate functioning within the range of typically developing children of the same age as the child being rated while scores below 60 indicate a definite clinical case
Time frame: Open-Label Baseline, Week 28, Week 52, and Week 104
Change From Baseline in Pediatric Quality of Life Enjoyment and Satisfaction Questionnaire (PQ-LES-Q) Percentage Maximum Possible Score
Change from Baseline in Pediatric Quality of Life Enjoyment and Satisfaction Questionnaire (PQ-LES-Q) Percentage Maximum Possible Score for subjects continued from study D1050326 The Pediatric Q-LES-Q is a 15-item self-report measure of the degree of enjoyment and satisfaction in various areas of daily living, based on the content of the Short From of the Q-LES-Q. Each item is rated on a 5-point scale, ranging from 1 (very poor) to 5 (very good). The first 14 items are the same as the General Activities section of the regular Q-LES-Q form and are used to compute the raw score. The PQ-LES-Q-SF percentage maximum possible score is calculated as follows: % Max = 100 × (Raw Score - Minimum Score) / (Maximum Score - Minimum Score), where the Minimum Score equals 14 and the Maximum Score equals 70, and the % maximum possible score can range from 0% to 100%. Higher scores indicate better quality of life.
Time frame: Open-Label Baseline, Week 28, Week 52, and Week 104
Change From Baseline in Pediatric Anxiety Rating Scale (PAR) Total Score
Change from Baseline in PAR Total Score for subjects continued from study D1050326 The PARS is a clinician-rated instrument for assessing over time the severity of anxiety symptoms associated with common DSM-IV anxiety disorders in children ages 6 17 years. The PARS is administered separately to the subject and to the caregiver. The instrument has 2 sections. The first section includes a 50-item symptom checklist, which the clinician rates as present or absent during the past week. The second section is comprised of 7 severity impairment items reflecting the severity/impairment of all symptoms endorsed in Section 1 of the PARS (during the past week). Each question is answered on a 0-5 Likert scale (0 for none, and 1-5 for minimal to extreme) with alternative responses of 8=Not Applicable and 9=Does Not Know. Scores of 8 or 9 are not counted in the summation as per the PARS instructions. The PARS total score over all 7 questions ranges in value from 0 to 35.A higher PARS total score
Time frame: Open-Label Baseline, Week 28, Week 52, and Week 104
Change From Baseline in Attention-Deficity/Hyperactivity Disorder Rating Scale (ADHD-RS) Total Score
Change from Baseline in Attention-Deficity/Hyperactivity Disorder Rating Scale (ADHD-RS) Total Score for subjects continued from study D1050326 The ADHD-RS IV is a validated scale that measures the behaviors of children with ADHD. The ADHD-RS IV consists of 18 items reflecting current symptomatology of ADHD based on DSM-IV-TR criteria. Each item is scored from a range of 0 (no symptoms) to 3 (severe symptoms) with total scores ranging from 0 to 54. The 18 items may be grouped into two sub-scales: hyperactivity/impulsivity (even number items 2 through 18) and inattentiveness (odd number items 1 through 17), ranging from 0 to 27. A higher ADHD-RS total score and sub-scales scores are associated with greater illness severity
Time frame: Open-Label Baseline, Week 28, Week 52, and Week 104
participation in the preceding double-blind efficacy and safety studies (D1050301, NCT01911429,; D1050325, NCT01911442; or D1050326, NCT02046369) were eligible for enrollment in this study.
| Milestone | Rollover From D1050301 | Rollover From D1050325 | Rollover From D1050326 |
|---|---|---|---|
| Started | 271 | 125 | 306 |
| Completed | 156 | 54 | 168 |
| Not completed | 115 | 71 | 138 |
| Withdrew: Protocol violation | 11 | 3 | 19 |
| Withdrew: Lack of efficacy | 11 | 16 | 5 |
| Withdrew: No reason given | 14 | 8 | 16 |
| Withdrew: Adverse event | 29 | 18 | 31 |
| Withdrew: Withdrawal by subject | 38 | 20 | 47 |
| Withdrew: Lost to follow-up | 12 | 6 | 19 |
| Withdrew: Subject never dosed | 0 | 0 | 1 |
The Safety population consists of all subjects who received at least one dose of study drug in this study.
| Participants | Rollover From D1050301 | Rollover From D1050325 | Rollover From D1050326 | Lurasidone (All Indications) |
|---|---|---|---|---|
| Subjects with at least one treatment emergent AE | 214 | 106 | 252 | 572 |
| Subjects with at least one treatment emergent SAE | 28 | 13 | 37 | 78 |
| Subjects with AE Leading to Discontinuation | 28 | 18 | 31 | 77 |
Change from Baseline in the Positive and Negative Syndrome Scale (PANSS) Total Score for subjects continued from study D1050301. PANSS is comprised of 30 items and 3 subscales (Positive, Negative, General Psychopathology). An anchored Likert scale from 1 - 7, where values of 2 and above indicate the presence of progressively more severe symptoms, is used to score each item. Individual items are then summed to determine scores for the 3 subscales, as well as a total score. PANSS Positive subscale score range: 7-49. PANSS Negative subscale score range: 7-49. PANSS General Psychopathology subscale score range: 16-112. PANSS total score range: 30-210 Higher values of PANSS total score represents greater severity of illness.
| units on a scale | Rollover From D1050301 |
|---|---|
| Open Label Baseline | 76.0 ± 17.72 |
| Week 28 | -11.9 ± 13.74 |
| Week 52 | -15.6 ± 14.97 |
| Week 104 | -18.4 ± 16.73 |
Change from Baseline in PANSS Positive Subscale Score for subjects continued from study D1050301 The Positive scale contains seven questions to assess delusions, conceptual disorganization, hallucinations behavior, excitement, grandiosity, suspiciousness /persecution, and hostility; Positive subscale (range 7-49) is calculated as sum of Items P1 to P7 in the positive subscale Higher values of PANSS sub-scale scores represent greater severity
| units on a scale | Rollover From D1050301 |
|---|---|
| Open Label baseline | 17.9 ± 5.51 |
| Week 28 | -3.9 ± 4.68 |
| Week 52 | -5.1 ± 5.13 |
| Week 104 | -5.4 ± 5.66 |
Change from Baseline in PANSS Negative Subscale Score for subjects continued from study D1050301 The Negative scale contains seven questions to assess blunted effect, emotional withdrawal, poor rapport, passive/apathetic social withdrawal, lack of motivation, and similar symptoms; Negative subscale (range 7-49) is calculated as sum of Items N1 to N7 in the negative subscale Higher values of PANSS sub-scale scores represent greater severity of illness.
| units on a scale | Rollover From D1050301 |
|---|---|
| Open Label baseline | 20.5 ± 4.91 |
| Week 28 | -2.6 ± 4.16 |
| Week 52 | -3.4 ± 4.34 |
| Week 104 | -4.3 ± 4.77 |
Change from Baseline in PANSS General Psychopathology Subscale Score for subjects continued from study D1050301 The General Psychopathology subscale addresses other symptoms such as anxiety, somatic concern, and disorientation; General psychopathology subscale (range 16-112) is calculated as sum of Items G1 to G16 in the general psychopathology subscale Higher values of PANSS sub-scale scores represent greater severity of illness.
| units on a scale | Rollover From D1050301 |
|---|---|
| Open label baseline | 37.5 ± 9.38 |
| Week 28 | -5.4 ± 7.28 |
| Week 52 | -7.2 ± 7.65 |
| Week 104 | -8.7 ± 8.68 |
Change from Baseline in PANSS Excitability Subscale Score for subjects continued from study D1050301 Subscale of Excitability consists of the following four items from the PANSS: excitement, hostility, uncooperativeness, and poor impulse control. The sum of the four items ranges from 4 to 28 Higher values of PANSS sub-scale scores represent greater severity of illness.
| units on a scale | Rollover From D1050301 |
|---|---|
| Open label baseline | 9.0 ± 3.73 |
| Week 28 | -1.3 ± 3.09 |
| Week 52 | -1.7 ± 3.31 |
| week 104 | -2.1 ± 3.63 |
Change from Baseline in the Clinical Global Impression -Severity Score for subjects continued from study D1050301 The CGI-S is a single value, clinician-rated assessment of illness severity, and 7-point scale with range from 1='Normal, not at all ill' to 7='Among the most extremely ill patients'. A higher score is associated with greater illness severity
| units on a scale | Rollover From D1050301 |
|---|---|
| Open label baseline | 4.0 ± 0.97 |
| Week 28 | -0.87 ± 0.941 |
| Week 52 | -1.10 ± 1.084 |
| Week 104 | -1.31 ± 1.196 |
Change from Baseline in Clinician-Rated Children's Global Assessment Score (CGAS) Score for subjects continued from study D1050301 The Children's Global Assessment Scale (CGAS) is a numeric scale (1 through 100) used by mental health clinicians to rate the general functioning of children under the age of 18, where 1 represents the most impaired functioning and 100, superior functioning. Each decile (e.g., 1-10, 11-20) has a descriptive header (e.g., "Moderate impairment in functioning in most domains") and examples of behaviors and types of environmental accommodations that might be seen at that level of functioning. Scores above 70 on the CGAS indicate functioning within the range of typically developing children of the same age as the child being rated while scores below 60 indicate a definite clinical case
| units on a scale | Rollover From D1050301 |
|---|---|
| Open label baseline | 55.0 ± 11.96 |
| Week 28 | 10.94 ± 11.943 |
| Week 52 | 14.28 ± 12.814 |
| Week 104 | 17.85 ± 15.155 |
Change from Baseline in Pediatric Quality of Life Enjoyment and Satisfaction Questionnaire (PQ-LES-Q) Percentage Maximum Possible Score for subjects continued from study D1050301 The Pediatric Q-LES-Q is a 15-item self-report measure of the degree of enjoyment and satisfaction in various areas of daily living, based on the content of the Short From of the Q-LES-Q. Each item is rated on a 5-point scale, ranging from 1 (very poor) to 5 (very good). The first 14 items are the same as the General Activities section of the regular Q-LES-Q form and are used to compute the raw score. The PQ-LES-Q-SF percentage maximum possible score is calculated as follows: % Max = 100 × (Raw Score - Minimum Score) / (Maximum Score - Minimum Score), where the Minimum Score equals 14 and the Maximum Score equals 70, and the % maximum possible score can range from 0% to 100%. Higher scores indicate better quality of life.
| percent of score | Rollover From D1050301 |
|---|---|
| Open label baseline | 57.14 ± 14.850 |
| Week 28 | 7.48 ± 13.336 |
| Week 52 | 9.98 ± 13.541 |
| Week 104 | 11.74 ± 15.783 |
Change from Baseline in ABC Irritability Subscale Score for subjects continued from study D1050325 The Aberrant Behavior Checklist (ABC) contains 58 items resolve into five subscales: (1) irritability and agitation (15 items), (2) lethargy and social withdrawal (16 items), (3) stereotypic behavior (7 items), (4) hyperactivity and noncompliance (16 items), and (5) inappropriate speech (4 items). Each item is rated for severity on a 4-point Likert scale ranging from 0 (not at all a problem) to 3 (the problem is severe in degree). Irritability Subscale Score is calculated as summing of items 2, 4, 8, 10, 14, 19, 25, 29, 34, 36, 41, 47, 50, 52, and 57; as a result, ABC irritability subscale score ranges from 0 to 45. In general, higher values of ABC subscale scores represent greater severity of illness. If one or more items are missing, no imputation was performed and the scores of the subscales that include these items was left missing
| units on a scale | Rollover From D1050325 |
|---|---|
| Open label baseline | 19.0 ± 10.63 |
| Week 28 | -2.1 ± 9.16 |
| Week 52 | -2.9 ± 9.85 |
| Week 104 | -4.2 ± 11.62 |
Change from Baseline in ABC Lethargy and Social Withdrawal Subscale Score for subjects continued from study D1050325 The ABC contains 58 items resolve into five subscales: (1) irritability and agitation (15 items), (2) lethargy and social withdrawal (16 items), (3) stereotypic behavior (7 items), (4) hyperactivity and noncompliance (16 items), and (5) inappropriate speech (4 items). Each item is rated for severity on a 4-point Likert scale ranging from 0 (not at all a problem) to 3 (the problem is severe in degree). Lethargy and Social Withdrawal Subscale Score is calculated as summing of items 3, 5, 12, 16, 20, 23, 26, 30, 32, 37, 40, 42, 43, 53, 55, and 58. ABC Lethargy and Social Withdrawal Subscale Score ranges from 0 to 48. In general, higher values of ABC subscale scores represent greater severity of illness. If one or more items are missing, no imputation was performed and the scores of the subscales that include these items was left missing
| score | Rollover From D1050325 |
|---|---|
| Open label baseline | 10.3 ± 9.48 |
| Week 28 | -0.7 ± 7.01 |
| Week 52 | -1.1 ± 6.94 |
| Week 104 | -1.1 ± 6.57 |
Change from Baseline in ABC Stereotypic Behavior Subscale Score for subjects continued from study D1050325. The ABC contains 58 items resolve into five subscales: (1) irritability and agitation (15 items), (2) lethargy and social withdrawal (16 items), (3) stereotypic behavior (7 items), (4) hyperactivity and noncompliance (16 items), and (5) inappropriate speech (4 items). Stereotypic behavior Subscale Score is calculated as summing of 6, 11, 17, 27, 35, 45, and 49 items . ABC Stereotypic behavior Subscale Score ranges from 0 to 21. Each item is rated for severity on a 4-point Likert scale ranging from 0 (not at all a problem) to 3 (the problem is severe in degree). To score the ABC, the individual items for each subscale are simply summed to their respective totals. It is inappropriate to compute a "total aberrant score", based on a summation of all 58 items, as the subscales are largely independent. In general, higher values of ABC subscale scores represent greater severity
| score | Rollover From D1050325 |
|---|---|
| Open label baseline | 6.1 ± 5.87 |
| Week 28 | -0.9 ± 3.55 |
| Week 52 | -0.9 ± 4.53 |
| Week 104 | -1.1 ± 4.41 |
Change from Baseline in ABC Hyperactivity and Noncompliance Subscale Score for subjects continued from study D1050325 The ABC contains 58 items resolve into five subscales: (1) irritability and agitation (15 items), (2) lethargy and social withdrawal (16 items), (3) stereotypic behavior (7 items), (4) hyperactivity and noncompliance (16 items), and (5) inappropriate speech (4 items). Each item is rated for severity on a 4-point Likert scale ranging from 0 (not at all a problem) to 3 (the problem is severe in degree). Hyperactivity and noncompliance Subscale Score is calculated as summing of 1, 7, 13, 15, 18, 21, 24, 28, 31, 38, 39, 44, 48, 51, 54, and 56 items. ABC hyperactivity and noncompliance Subscale Score ranges from 0 to 48. In general, higher values of ABC subscale scores represent greater severity of illness. If one or more items are missing, no imputation was performed and the scores of the subscales that include these items was left missing
| score | Rollover From D1050325 |
|---|---|
| Open label baseline | 24.1 ± 12.19 |
| Week 28 | -3.8 ± 10.16 |
| Week 52 | -4.3 ± 11.24 |
| Week 104 | -5.6 ± 12.84 |
Change from Baseline in ABC Inappropriate Speech Subscale Score for subjects continued from study D1050325 The ABC contains 58 items resolve into five subscales: (1) irritability and agitation (15 items), (2) lethargy and social withdrawal (16 items), (3) stereotypic behavior (7 items), (4) hyperactivity and noncompliance (16 items), and (5) inappropriate speech (4 items). Each item is rated for severity on a 4-point Likert scale ranging from 0 (not at all a problem) to 3 (the problem is severe in degree). Inappropriate speech Subscale Score is calculated as summing of 9, 22, 33, and 46 items. ABC inappropriate speech Subscale Score ranges from 0 to 12. In general, higher values of ABC subscale scores represent greater severity of illness. If one or more items are missing, no imputation was performed and the scores of the subscales that include these items was left missing
| score | Rollover From D1050325 |
|---|---|
| Open label baseline | 5.2 ± 3.61 |
| Week 28 | -0.7 ± 2.75 |
| Week 52 | -0.7 ± 2.88 |
| Week 104 | -0.5 ± 3.00 |
Change from Baseline in Clinical Global Impression (CGI) - Severity Score for subjects continued from study D1050325 The CGI-S is a single value, clinician-rated assessment of illness severity, and 7-point scale with range from 1='Normal, not at all ill' to 7='Among the most extremely ill patients'. A higher score is associated with greater illness severity
| units on a scale | Rollover From D1050325 |
|---|---|
| Open label baseline | 3.9 ± 1.25 |
| Week 28 | -0.43 ± 0.984 |
| Week 52 | -0.71 ± 1.078 |
| Week 104 | -0.78 ± 1.313 |
Change from Baseline in CY-BOCS for subjects continued from study D1050325 CY-BOCS used in the study is a modification of the Yale-Brown Obsessive Compulsive Scale and contains total 7 items for compulsion. "Obsessions" section was removed as it is difficult to obtain valid information given typical language/cognitive delays in the population. Each item of the compulsive scale ranges from 0 to 4. At this time, item 1b ("compulsion-free interval") and item 6 ("peculiarity of the behavior") are not being used in the scoring. Item 7 is a rating for reliability, ranging from 0 (excellent) to 3 (poor). It reflects the interview's judgment regarding the confidence in the data collected hence it is not counted in the CY-BOCS total score. The CY-BOCS compulsion total score is the sums of item 1-5. As a result, the CY-BOCS compulsion total score may range from 0 to 20. In general, higher values of CY-BOCS scores represent greater severity of illness
| units on a scale | Rollover From D1050325 |
|---|---|
| Open label baseline | 10.2 ± 5.43 |
| Week 28 | -2.2 ± 3.39 |
| Week 52 | -2.3 ± 4.32 |
| Week 104 | -3.2 ± 4.58 |
Change from Baseline in Caregiver Strain Questionnaire (CGSQ) Global Strain Score for subjects continued from study D1050325 The CGSQ is comprised of total 21 items. Each item is rated on a 5-point Likert-type scale (1 (not at all a problem) to 5 (very much a problem)) and is grouped into three subscales: objective strain, subjective externalized strain, and subjective internalized strain. The 3 subscale scores are calculated as the averages of the corresponding individual items, which range in severity from 1 to 5. Higher scores on each of these subscale scales indicate greater strain. A global strain score is calculated by summing the three subscales (i.e., objective strain, subjective externalized strain, and subjective internalized strain) to provide an indication of the total impact of the special demands on the family. Global strain scores range from 3 to 15. As with the individual subscales, higher scores indicate greater strain
| score | Rollover From D1050325 |
|---|---|
| Open label baseline | 7.95 ± 2.213 |
| Week 28 | -0.48 ± 1.887 |
| Week 52 | -0.60 ± 2.032 |
| Week 104 | -0.63 ± 2.123 |
Change from Baseline in CDRS-R Total Score for subjects continued from study D1050326 CDRS-R is a semi-structured, clinician-rated instrument designed for use with children and adolescents between the ages of 6 17 years. It contains 17 ordinally-scaled items that evaluate the presence and severity of symptoms commonly associated with depression in childhood. The CDRS-R is administered separately to the patient and to the caregiver; among 17 items, 14 items are based on separate interviews with child and parent, 3 items are based solely on the rater's observation of child (ie, no questions).The 14 items are rated on a 1 (no psychopathology) to 7 (most psychopathology) scale, where a rating of 3 represents mild psychopathology. The 3 items (sleep disturbance, appetite disturbance, listless speech) are rated on a 1 (no pathology) to 5 (most pathology) scale. The CDRS-R total score ranges from 17-113. In general, higher values of CDRS-R total score represent greater severity of illness
| units on a scale | Rollover From D1050326 |
|---|---|
| Open label baseline | 39.2 ± 13.38 |
| Week 28 | -9.9 ± 13.48 |
| Week 52 | -13.4 ± 13.01 |
| Week 104 | -16.4 ± 13.24 |
Change from Baseline in Clinical Global Impression Bipolar Version (CGI-BP-S) Depression Score for subjects continued from study D1050326 The CGI-BP-S is a three-question clinician-rated assessment of the subject's current illness state (depression, mania, and overall) using a 7-point scale (1(normal, not ill) to 7 (very severely ill)) for each question, where a higher score is associated with greater illness severity.
| units on a scale | Rollover From D1050326 |
|---|---|
| Open label baseline | 3.2 ± 1.09 |
| Week 28 | -1.10 ± 1.140 |
| Week 52 | -1.36 ± 1.184 |
| Week 104 | -1.61 ± 1.153 |
Change from Baseline in Clinician-rated Children's Global Assessment Scale (CGAS) Score for subjects continued from study D1050326 The Children's Global Assessment Scale (CGAS) is a numeric scale (1 through 100) used by mental health clinicians to rate the general functioning of children under the age of 18, where 1 represents the most impaired functioning and 100, superior functioning. Each decile (e.g., 1-10, 11-20) has a descriptive header (e.g., "Moderate impairment in functioning in most domains") and examples of behaviors and types of environmental accommodations that might be seen at that level of functioning. Scores above 70 on the CGAS indicate functioning within the range of typically developing children of the same age as the child being rated while scores below 60 indicate a definite clinical case
| units on a scale | Rollover From D1050326 |
|---|---|
| Open label baseline | 61.1 ± 12.54 |
| Week 28 | 11.17 ± 13.893 |
| Week 52 | 14.67 ± 14.347 |
| Week 104 | 18.96 ± 14.898 |
Change from Baseline in Pediatric Quality of Life Enjoyment and Satisfaction Questionnaire (PQ-LES-Q) Percentage Maximum Possible Score for subjects continued from study D1050326 The Pediatric Q-LES-Q is a 15-item self-report measure of the degree of enjoyment and satisfaction in various areas of daily living, based on the content of the Short From of the Q-LES-Q. Each item is rated on a 5-point scale, ranging from 1 (very poor) to 5 (very good). The first 14 items are the same as the General Activities section of the regular Q-LES-Q form and are used to compute the raw score. The PQ-LES-Q-SF percentage maximum possible score is calculated as follows: % Max = 100 × (Raw Score - Minimum Score) / (Maximum Score - Minimum Score), where the Minimum Score equals 14 and the Maximum Score equals 70, and the % maximum possible score can range from 0% to 100%. Higher scores indicate better quality of life.
| score | Rollover From D1050326 |
|---|---|
| Open label baseline | 59.52 ± 15.569 |
| Week 28 | 8.16 ± 16.345 |
| Week 52 | 11.37 ± 16.343 |
| Week 104 | 14.75 ± 16.744 |
Change from Baseline in PAR Total Score for subjects continued from study D1050326 The PARS is a clinician-rated instrument for assessing over time the severity of anxiety symptoms associated with common DSM-IV anxiety disorders in children ages 6 17 years. The PARS is administered separately to the subject and to the caregiver. The instrument has 2 sections. The first section includes a 50-item symptom checklist, which the clinician rates as present or absent during the past week. The second section is comprised of 7 severity impairment items reflecting the severity/impairment of all symptoms endorsed in Section 1 of the PARS (during the past week). Each question is answered on a 0-5 Likert scale (0 for none, and 1-5 for minimal to extreme) with alternative responses of 8=Not Applicable and 9=Does Not Know. Scores of 8 or 9 are not counted in the summation as per the PARS instructions. The PARS total score over all 7 questions ranges in value from 0 to 35.A higher PARS total score
| units on a scale | Rollover From D1050326 |
|---|---|
| Open label baseline | 8.0 ± 6.94 |
| Week 28 | -2.7 ± 5.41 |
| Week 52 | -3.2 ± 5.97 |
| Week 104 | -4.9 ± 6.41 |
Change from Baseline in Attention-Deficity/Hyperactivity Disorder Rating Scale (ADHD-RS) Total Score for subjects continued from study D1050326 The ADHD-RS IV is a validated scale that measures the behaviors of children with ADHD. The ADHD-RS IV consists of 18 items reflecting current symptomatology of ADHD based on DSM-IV-TR criteria. Each item is scored from a range of 0 (no symptoms) to 3 (severe symptoms) with total scores ranging from 0 to 54. The 18 items may be grouped into two sub-scales: hyperactivity/impulsivity (even number items 2 through 18) and inattentiveness (odd number items 1 through 17), ranging from 0 to 27. A higher ADHD-RS total score and sub-scales scores are associated with greater illness severity
| units on a scale | Rollover From D1050326 |
|---|---|
| Open label baseline | 9.4 ± 10.58 |
| Week 28 | -2.2 ± 6.29 |
| Week 52 | -2.4 ± 5.83 |
| Week 104 | -3.3 ± 6.24 |
Collected over An AE onset on or after the start of the open-label treatment period (treatment duration: 104 weeks) through 7 days after study drug discontinuation (14 days for serious adverse events and deaths). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Rollover From D1050301 | 0/271 (0%) | 28/271 (10.3%) | 184/271 (67.9%) |
| Rollover From D1050325 | 0/125 (0%) | 13/125 (10.4%) | 94/125 (75.2%) |
| Rollover From D1050326 | 0/305 (0%) | 37/305 (12.1%) | 198/305 (64.9%) |
| Total D1050302 | 0/701 (0%) | 78/701 (11.1%) | 560/701 (79.9%) |
| Event | Rollover From D1050301 | Rollover From D1050325 | Rollover From D1050326 | Total D1050302 |
|---|---|---|---|---|
| SchizophreniaPsychiatric disorders | 11/271 | 0/125 | 0/305 | 11/701 |
| Suicidal ideationPsychiatric disorders | 8/271 | 1/125 | 5/305 | 14/701 |
| AggressionPsychiatric disorders | 1/271 | 3/125 | 0/305 | 4/701 |
| Suicide attemptPsychiatric disorders | 1/271 | 1/125 | 6/305 | 8/701 |
| Bipolar I disorderPsychiatric disorders | 0/271 | 0/125 | 6/305 | 6/701 |
| Psychotic disorderPsychiatric disorders | 5/271 | 0/125 | 0/305 | 5/701 |
| Bipolar disorderPsychiatric disorders | 0/271 | 0/125 | 4/305 | 4/701 |
| DepressionPsychiatric disorders | 1/271 | 0/125 | 3/305 | 4/701 |
| Violence-related symptomPsychiatric disorders | 0/271 | 1/125 | 0/305 | 1/701 |
| Hand fractureInjury, poisoning and procedural complications | 0/271 | 1/125 | 2/305 | 3/701 |
| Event | Rollover From D1050301 | Rollover From D1050325 | Rollover From D1050326 | Total D1050302 |
|---|---|---|---|---|
| HeadacheNervous system disorders | 65/271 | 18/125 | 73/305 | 156/701 |
| NasopharyngitisInfections and infestations | 24/271 | 28/125 | 26/305 | 78/701 |
| VomitingGastrointestinal disorders | 16/271 | 27/125 | 25/305 | 68/701 |
| NauseaGastrointestinal disorders | 34/271 | 9/125 | 50/305 | 93/701 |
| Weight increasedInvestigations | 21/271 | 20/125 | 29/305 | 70/701 |
| AnxietyPsychiatric disorders | 35/271 | 14/125 | 26/305 | 75/701 |
| SomnolenceNervous system disorders | 24/271 | 14/125 | 30/305 | 68/701 |
| Upper respiratory tract infectionInfections and infestations | 10/271 | 14/125 | 12/305 | 36/701 |
| AgitationPsychiatric disorders | 20/271 | 14/125 | 11/305 | 45/701 |
| CoughRespiratory, thoracic and mediastinal disorders | 11/271 | 14/125 | 14/305 | 39/701 |
There was one subject that never received study drug bringing the baseline population from 702 to 701
| Age, Continuous(years) | Rollover From D1050301 | Rollover From D1050325 | Rollover From D1050326 | Total |
|---|---|---|---|---|
| Mean | 15.5 ± 1.44 | 11.1 ± 3.12 | 14.4 ± 2.18 | 14.3 ± 2.66 |
| Age, Customized(participants) | Rollover From D1050301 | Rollover From D1050325 | Rollover From D1050326 | Total |
|---|---|---|---|---|
| Children (2-11 years) | 0 | 75 | 36 | 111 |
| Adolescents (12-17 years) | 257 | 50 | 258 | 565 |
| Adults (18-64 years) | 14 | 0 | 11 | 25 |
| Sex: Female, Male(Participants) | Rollover From D1050301 | Rollover From D1050325 | Rollover From D1050326 | Total |
|---|---|---|---|---|
| Female | 101 | 23 | 152 | 276 |
| Male | 170 | 102 | 153 | 425 |
| Ethnicity (NIH/OMB)(Participants) | Rollover From D1050301 | Rollover From D1050325 | Rollover From D1050326 | Total |
|---|---|---|---|---|
| Hispanic or Latino | 36 | 21 | 54 | 111 |
| Not Hispanic or Latino | 235 | 104 | 251 | 590 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Rollover From D1050301 | Rollover From D1050325 | Rollover From D1050326 | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 2 | 2 | 4 |
| Asian | 11 | 2 | 10 | 23 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 |
| Black or African American | 38 | 21 | 26 | 85 |
| White | 197 | 96 | 235 | 528 |
| More than one race | 25 | 4 | 32 | 61 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
| Region of Enrollment(Participants) | Rollover From D1050301 | Rollover From D1050325 | Rollover From D1050326 | Total |
|---|---|---|---|---|
| North America | 82 | 125 | 125 | 332 |
| South America | 21 | 0 | 40 | 61 |
| Europe | 157 | 0 | 131 | 288 |
| Asia | 11 | 0 | 9 | 20 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Sep 2013 to primary completion in Oct 2018, 60 months.
Results were first posted in Dec 2019, 1 year 2 months after primary completion.
Of 99 industry-sponsored phase 3 interventional studies under Schizophrenia, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 41. This study's 60 months is above that.
Counting every sponsor, half of 113 studies reached it within 32 months; a quarter within 20 and three quarters within 46.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Lurasidone
Sumitomo Pharma America, Inc. →